Creating awareness in the Hispanic/Latino Community through events nationwide has been the main goal of NLAAD through the years. Now that restrictions due to COVID-19 are not as strict as previous years we hope we can organize live events again. We won’t dismay in our efforts to end the HIV epidemic, and to deliver information and...
Tuesday October 4th, 3pm “A different PrEP Option: A Presentation for PrEP Professionals” Apretude is the first and only long acting injectable PrEP for reducing the risk of getting HIV. Join us to this presentation given by ViiV laboratories with information about this new important medical advance in the HIV field. [Registration link] Wednesday...
New York, September 15, 2022- October 15th is National Latinx AIDS Awareness Day (NLAAD). NLAAD’s campaign brings together Hispanic/Latinx communities and service providers, and organizations providing services to Hispanic/Latinx throughout the U.S. and territories under one theme. This year’s theme “You Choose!” informs us about new developments in the scientific field of HIV, that provide us...
TITUSVILLE, N.J., February 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved an expanded label for CABENUVA (rilpivirine and cabotegravir) to be administered every two months for the treatment of HIV-1 in virologically suppressed adults (HIV-1 RNA less than 50 copies per...
London, 21 December 2021 – ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. (Pfizer) and Shionogi Limited (Shionogi) as shareholders, today announced that the US Food and Drug Administration (FDA) approved Apretude, the first and only long-acting injectable pre-exposure prophylaxis (PrEP) option to reduce the risk of sexually...
